Clinigen Limited has entered into an agreement to divest Proleukin to Iovance Biotherapeutics. Terms of the agreement include an upfront payment of GBP 166.7M, a GBP 41.7M milestone payment upon first approval of lifileucel in advanced melanoma, and double-digit Proleukin global sales royalties from Iovance to Clinigen. The transaction is expected to close in the first quarter of 2023, subject to required regulatory approvals and clearances and other customary closing conditions.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IOVA:
- Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
- Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics
- Barclays views GSK acquisition interest as positive for oncology stocks
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
